Commercialization: Page 23

PharmaVoice Team/PharmaVoice

Is the Rare Disease Business Model Here to Stay?

These days, the term “rare disease" is well ingrained in our everyday vernacular — but that hasn’t always been the case. The pharmaceutical industry paid little attention to developing new treatments for rare disease prior to the Reagan Administration’s implementation of the Orphan Drug Act (ODA)...
By Scott D. Hibbard • Feb. 1, 2019
PharmaVoice Team/PharmaVoice

From Scientific Discovery to Real World Application: the "Future" of Medicine is Here

I vividly remember the day in February of 2001 when the nearly complete sequence of the human genome was first published. My cellular and molecular biology professor had unfolded a giant poster from the journal Nature and revealed those approximately 30,000 genes to our class. Amazingly, in less ...
By Jahda Hill • Feb. 1, 2019
PharmaVoice Team/PharmaVoice

Executive Perspective: A Fused Model for the Enterprise - A Conversation with Brian Williams

Winning in today’s digital era requires more than just apps and a website. Fusing an enterprise for success in the digital era requires companies to seamlessly collaborate across the enterprise and create a true strategic pathway for a better customer experience. Recently, Cognizant commissioned ...
By Brian Williams • Feb. 1, 2019
PharmaVoice Team/PharmaVoice

Red Zone: Disruptive Innovation: Questions for the C-Suite

It is not the strongest of the species that survives, nor is it the most intelligent. It is the one that is most adaptable to change. Whether a direct quote from Charles Darwin or a summary of his writings, this statement is perhaps the most profound scientific explanation of life itself, in all ...
By Srini Shankar • Feb. 1, 2019
PharmaVoice Team/PharmaVoice

Letter from the Editor

Artificial Intelligence Happy New Year. As we enter 2019, we take note of one of the major trends expected to impact all aspects of the life-sciences industry: artificial intelligence. In 2019, according to Forrester, AI solutions will continue to spread across the healthcare continuum thanks to ...
By Taren Grom • Jan. 1, 2019
PharmaVoice Team/PharmaVoice

Upfront

Medicinal Theater BioMarin Pharmaceutical and Believe Ltd. sponsored a first-of-its-kind theatrical production for teenagers with hemophilia. The musical, Hemophilia: The Musical, took place at New World Stages on Nov. 12, 2018. Before the performance, students participated in the Breaking Throug...
By PharmaVoice Team • Jan. 1, 2019
PharmaVoice Team/PharmaVoice

HealthTech

Payers Use Healthtech to Improve Patient Outcomes, Lower Costs Trend Watch: Healthtech Mobile App Market Continues To Grow Payers Offer Free Wearables UnitedHealthcare, Aetna, and John Hancock have all implemented programs that offer free Apple Watches to customers, if they exercise daily. The la...
By PharmaVoice Team • Jan. 1, 2019
PharmaVoice Team/PharmaVoice

Artificial Intelligence

Artificial Intelligence Key to Improving Healthcare Quality, Reducing Costs Trend Watch: AI Implications for Healthcare are Widespread Artificial Intelligence (AI) is key to building a better healthcare future, according to a recent survey of 500 U.S. healthcare leaders on their attitudes and usa...
By PharmaVoice Team • Jan. 1, 2019
PharmaVoice Team/PharmaVoice

Last Word

Combating Opioid Addiction Sarah Akerman, M.D., Senior Medical Director at Alkermes, talks about the industry’s role in opioid use disorder. PV: What are some of the biggest issues around the current treatment system for addiction? Akerman: The current treatment system for opioid addiction is ina...
By Sarah Akerman • Jan. 1, 2019
PharmaVoice Team/PharmaVoice

Artificial Intelligence: Molecule to Market

The adoption of artificial intelligence (AI) is rapidly taking hold across global businesses, including the life-sciences industry. AI is typically defined as the ability of a machine to perform cognitive functions associated with human minds, such as perceiving, reasoning, learning, and problem ...
By PharmaVoice Team • Jan. 1, 2019
PharmaVoice Team/PharmaVoice

SHOWCASE: Social Media: A Strategic Approach: Key to Social Media Success

Data from the second quarter of 2018 show that Facebook had 2.23 billion monthly active users, while Twitter had 326 million active users in the third quarter of 2018. Consumers use social media for many reasons today, including to learn about a medicine or illness. The use of social media forums...
By PharmaVoice Team • Jan. 1, 2019
PharmaVoice Team/PharmaVoice

2019 Social Media Trends for Pharma

In a relatively short period of time, social media has reshaped communication for consumers and healthcare professionals alike. No longer are users simply posting content and communicating amongst themselves — social channels are now dominated by media reaching specifically targeted audiences. Lo...
By Brandie Linfante • Jan. 1, 2019
PharmaVoice Team/PharmaVoice

Drug Pricing Transparency: Will it be Now or Never?

In the ongoing clash between pharma and the Trump administration over pricing issues, CMS proposed a rule last year that would require pharmaceutical companies to include the price of any drug that cost more than $35 a month in their television ads. PhRMA preempted the salvo with a voluntary pled...
By Robin Robinson • Jan. 1, 2019
PharmaVoice Team/PharmaVoice

Red Zone: To Gain Competitive Advantage, Learn Your ABCDs

Understanding and staying engaged with patients throughout their treatment and wellness journey is a primary focus of the entire life sciences industry. The benefits are clear: • Patients’ trust in the therapy and its ecosystem grows • Longitudinal data on patient progress provides evidence for v...
By Sriraman Nagarajan • Jan. 1, 2019
PharmaVoice Team/PharmaVoice

Letter from the Editor

The year ahead… As we come to the end of 2018, it’s important to pause and reflect on not just where we’ve been, but where we are going as an industry. In 2018, we saw continuing uncertainty in terms of the Affordable Care Act. We welcomed Alex Azar as the new Secretary of Health and Human Servic...
By Taren Grom • Nov. 15, 2018
PharmaVoice Team/PharmaVoice

Last Word

In Her Shoes: Understanding the Female Patient Experience Elizabeth Bolgiano, Executive VP, Chief Human Resources Officer at AMAG Pharmaceuticals, discusses the company’s efforts to imagine “walking a mile" in its female patients’ shoes as they seek care for sexual health-related conditions. PV: ...
By Elizabeth Bolgiano • Nov. 15, 2018
PharmaVoice Team/PharmaVoice

Trend: Advanced Diagnostics and Precision Medicine

Healthcare is moving increasingly toward personalized approaches — tailoring treatment based on each patient’s unique disease. Precision medicine is well-established in oncology, with many cancers now characterized by their unique genomic alterations. In the past few years, the Food and Drug Admi...
By PharmaVoice Team • Nov. 15, 2018
PharmaVoice Team/PharmaVoice

Trend: Creating Shared Value

Shared value was first introduced by Michael Porter and Marc Kramer in their Harvard Business Review article in 2011. Since then, multiple industries have assessed how to implement shared value into their business practices. In other industries, companies need to work hard to find a public good t...
By Taren Grom • Nov. 15, 2018
PharmaVoice Team/PharmaVoice

Trend: Genetic Testing and Data Privacy and Ownership

Genetic testing is a booming market. According to reports, as of April 2018 more than 15 million people had taken direct-to-consumer genetic tests, and with prices for autosomal DNA tests now costing less than $100, they have become very accessible. Companies such as 23andMe, Ancestry.com, and My...
By Kim Ribbink • Nov. 15, 2018
PharmaVoice Team/PharmaVoice

Trend: Innovative Product Launches

Increasing complexity in the market and pressure on managing costs already create many challenges when it comes to new drug launches. Add to that the intricacies of innovative and combination drugs and the speed at which they need to launch, and challenges multiply. However, this shifting environ...
By Robin Robinson • Nov. 15, 2018
PharmaVoice Team/PharmaVoice

Trend: Multistakeholder Commercial Models

In the coming years, pharma will mobilize around engaging and accommodating a multitude of stakeholders to generate a competitive advantage. Long gone are the days of targeting healthcare providers as the entire commercial strategy. Simplicity in commercialization no longer exists and has been re...
By Robin Robinson • Nov. 15, 2018
PharmaVoice Team/PharmaVoice

Trend: Rare Disease Innovation

It’s been almost 120 years since the word gene was coined. Today, researchers are well on their way to manipulating genes to treat diseases. With only about 400 approved treatments for more than 7,000 rare diseases — 80% of which are caused by gene mutations — scientific advances are enabling gen...
By PharmaVoice Team • Nov. 15, 2018
PharmaVoice Team/PharmaVoice

Trend: Voice Assistants

Alexa, how will voice assistants impact the pharmaceutical commercial landscape in the next five years? Alexa is “not sure about that," but our experts have the answers as smart speakers and voice technology begin to penetrate not only healthcare, but the pharma commercialization process as well....
By Robin Robinson • Nov. 15, 2018
PharmaVoice Team/PharmaVoice

SHOWCASE: eSolutions: Changing the Face of Patient Empowerment

With so many new players entering the realm of eSolutions to drive patient engagement and patient empowerment, life-sciences companies ignore digital innovation at their peril. What exactly are eSolutions in the context of healthcare delivery? Over the past few years, eSolutions have become more ...
By PharmaVoice Team • Nov. 15, 2018
PharmaVoice Team/PharmaVoice

How Pharma Can Benefit From the EHR

The digital age has been making waves since the late 1900s and the electronic health record (EHR) industry is one small piece in a vast pool of digital channels available for pharmaceutical companies through which to message their brands. The EHR, or EMR (electronic medical record), has been an i...
By Kaitlyn Clark • Nov. 15, 2018